Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
631 Leser
Artikel bewerten:
(2)

Ethypharm announces the appointment of Éric CHEVALIER as Group Human Resources Director

SAINT-CLOUD, France, Oct. 4, 2024 /PRNewswire/ -- Denis DELVAL, President & CEO of the Ethypharm Group, announces the appointment of Éric CHEVALIER as Group Human Resources Director with effect from 1 October 2024.

Eric CHEVALIER - Group Human Resources Director of Ethypharm

With 20 years' experience in the Human Resources function, including 10 years in the pharmaceutical industry, Éric Chevalier brings a wealth of experience from a variety of sectors, giving him a global and operational vision of HR issues.

Throughout his career, Éric Chevalier has held key positions in leading companies. In particular, he was Director of Human Resources at Biogen for 4 years, after having been HR Manager for several industrial organisations at General Electric Healthcare. He began his career at Coca-Cola Entreprises, where he spent nine years as an HR generalist. 20 years of experience have enabled him to acquire a comprehensive and integrated vision of HR, as well as solid expertise in the various key areas of Human Resources.

More recently, as Director of Human Resources at AstraZeneca France, Éric Chevalier oversaw all HR activities in France against a backdrop of strong growth. He helped set up high-performance organisations while promoting an open and committed working environment, focused on developing the skills of all employees.

Éric CHEVALIER holds a Master 2 in Human Resources Management from CIFFOP - Université Panthéon Assas - Paris II, as well as a Master in Economics from Paris I Panthéon-Sorbonne.

Denis DELVAL, President & CEO of the Ethypharm Group, said: "The recruitment of this key position for the development and evolution of Ethypharm led me to call on an experienced professional. We are convinced that Eric, with his experience and people-centred approach, will be able to support our Group's growth while reinforcing a positive and committed corporate culture".

Eric CHEVALIER, newly appointed Director of Human Resources, added: "I am delighted to be joining Ethypharm and enthusiastic about helping to strengthen its position as a key international player in the pharmaceutical industry. I look forward to working with the teams to develop talent and foster a humane and collaborative working environment"

About Ethypharm

Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential medicines, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine.

Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.

Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations.

Our six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.

Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them.

To find out more about Ethypharm, visit http://www.ethypharm.com and follow us on Linkedin.

Media Contact: Avril PONNELLE - presse@ethypharm.com

Photo - https://mma.prnewswire.com/media/2523477/Eric_Chevalier_Ethypharm.jpg
Logo - https://mma.prnewswire.com/media/1917067/3701425/Ethypharm_Logo.jpg

Ethypharm Logo (PRNewsfoto/Ethypharm)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ethypharm-announces-the-appointment-of-eric-chevalier-as-group-human-resources-director-302267731.html

© 2024 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.